Viruses have two opposing faces. On the one hand, they can cause harm and disease. A virus may manifest directly as a contagious disease with a clinical pathology of varying significance. A viral infection can also have delayed consequences, and in rare cases may cause cellular transformation and cancer. On the other hand, viruses may provide hope: hope for an efficacious treatment of serious disease. Examples of the latter are the use of viruses as a vaccine, as transfer vector for therapeutic genes in a gene therapy setting, or, more directly, as therapeutic anticancer agent in an oncolytic-virus therapy setting. Already there is evidence for antitumor activity of oncolytic viruses. The antitumor efficacy seems linked to their capacity to induce a tumor-directed immune response. Here, we will provide an overview on the development of oncolytic viruses and their clinical evaluation from the Dutch perspective.
Get full access to this article
View all access options for this article.
References
1.
AbouEl, HassanM.A., Van der Meulen-MuilemanI., AbbasS., and KruytF.A. (2004). Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J. Virol., 78, 12243–12251.
2.
AlemanyR. (2012). Chapter four—Design of improved oncolytic adenoviruses. Adv. Cancer Res., 115, 93–114.
3.
AthertonM.J., and LichtyB.D. (2013). Evolution of oncolytic viruses: novel strategies for cancer treatment. Immunotherapy, 5, 1191–1206.
4.
BalversR.K., BelcaidZ., Van den HengelS.K., et al. (2014). Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus Delta24-RGD to infiltrating glioma. Viruses., 6, 3080–3096.
5.
BartlettD.L., LiuZ., SathaiahM., et al. (2013). Oncolytic viruses as therapeutic cancer vaccines. Mol. Cancer, 12, 103.
6.
BernardsR., SchrierP.I., HouwelingA., et al. (1983). Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. Nature, 305, 776–779.
7.
BoozariB., MundtB., WollerN., et al. (2010). Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. Gut, 59, 1416–1426.
8.
BreitbachC.J., de SilvaN.S., FallsT.J., et al. (2011). Targeting tumor vasculature with an oncolytic virus. Mol. Ther., 19, 886–894.
9.
BrouwerE., HavengaM.J., OphorstO., et al. (2007). Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther., 14, 211–219.
10.
BuijsP.R., Van EijckC.H., HoflandL.J., et al. (2014). Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Cancer Gene Ther., 21, 24–30.
11.
CaretteJ.E., OvermeerR.M., SchagenF.H., et al. (2004). Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. Cancer Res., 64, 2663–2667.
12.
CaretteJ.E., GraatH.C., SchagenF.H., et al. (2007). A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology, 361, 56–67.
13.
ChenL., and FliesD.B. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol., 13, 227–242.
14.
ColungaA.G., LaingJ.M., and AurelianL. (2010). The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Ther., 17, 315–327.
DautzenbergI.J., Van den WollenbergD.J., Van den HengelS.K., et al. (2014). Mammalian orthoreovirus T3D infects U-118 MG cell spheroids independent of junction adhesion molecule-A. Gene Ther., 21, 609–617.
17.
DaveR.V., JebarA.H., JenningsV.A., et al. (2014). Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses. Surgeon, 12, 210–220.
18.
De JongM., EssersJ., and Van WeerdenW.M. (2014). Imaging preclinical tumour models: improving translational power. Nat. Rev. Cancer, 14, 481–493.
19.
De LeeuwB., SuM., Ter HorstM., et al. (2006). Increased glia-specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elements. J. Neurosci. Res., 83, 744–753.
20.
De VrijJ., DautzenbergI.J., Van den HengelS.K., et al. (2012). A cathepsin-cleavage site between the adenovirus capsid protein IX and a tumor-targeting ligand improves targeted transduction. Gene Ther., 19, 899–906.
21.
DiaconuI., CerulloV., HirvinenM.L., et al. (2012). Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res., 72, 2327–2338.
22.
DonnellyO.G., Errington-MaisF., SteeleL., et al. (2013). Measles virus causes immunogenic cell death in human melanoma. Gene Ther., 20, 7–15.
23.
DoroninK., ShashkovaE.V., MayS.M., et al. (2009). Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum. Gene Ther., 20, 975–988.
24.
DuruptF., Koppers-LalicD., BalmeB., et al. (2012). The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses. Cancer Gene Ther., 19, 58–68.
25.
EdukullaR., WollerN., MundtB., et al. (2009). Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res., 69, 1448–1458.
26.
EndoY., SakaiR., OuchiM., et al. (2008). Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene, 27, 2375–2381.
27.
ErringtonF., WhiteC.L., TwiggerK.R., et al. (2008). Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther., 15, 1257–1270.
28.
FallauxF.J., Van der EbA.J., and HoebenR.C. (1999). Who's afraid of replication-competent adenoviruses?. Gene Ther., 6, 709–712.
29.
GaoY., Whitaker-DowlingP., GriffinJ.A., et al. (2009). Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Ther., 16, 44–52.
30.
GeoergerB., VassalG., OpolonP., et al. (2004). Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res., 64, 5753–5759.
31.
GeutskensS.B., Van der EbM.M., PlompA.C., et al. (2000). Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther., 7, 1410–1416.
32.
GrahamF.L., and Van der EbA.J. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology, 52, 456–467.
33.
GreenD.R., and KroemerG. (2009). Cytoplasmic functions of the tumour suppressor p53. Nature, 458, 1127–1130.
34.
GrillJ., LamfersM.L., Van BeusechemV.W., et al. (2002). The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol. Ther., 6, 609–614.
35.
GrosA., Martinez-QuintanillaJ., PuigC., et al. (2008). Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res., 68, 8928–8937.
36.
GuillermeJ.B., BoisgeraultN., RouloisD., et al. (2013). Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin. Cancer Res., 19, 1147–1158.
37.
GujarS.A., MarcatoP., PanD., and LeeP.W. (2010). Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol. Cancer Ther., 9, 2924–2933.
38.
GujarS., DielschneiderR., ClementsD., et al. (2013). Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol. Ther., 21, 338–347.
39.
GuoZ.S., LiuZ., BartlettD.L., et al. (2013). Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am. J. Cancer Res, 3, 1–20.
40.
HakkarainenT., SarkiojaM., LehenkariP., et al. (2007). Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum. Gene Ther., 18, 627–641.
41.
HangalapuraB.N., OosterhoffD., de GrootJ., et al. (2011). Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Res., 71, 5827–5837.
42.
HeidemanD.A., SteenbergenR.D., Van der TorreJ., et al. (2005). Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer. Mol. Ther., 12, 1083–1090.
43.
HendrickxR., StichlingN., KoelenJ., et al. (2014). Innate immunity to adenovirus. Hum. Gene Ther., 25, 265–284.
44.
HeoJ., ReidT., RuoL., et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med., 19, 329–336.
45.
HoebenR.C., and UilT.G. (2013). Adenovirus DNA replication. Cold Spring Harb. Perspect. Biol., 5, a013003.
46.
HoltermanL., VogelsR., Van der VlugtR., et al. (2004). Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J. Virol., 78, 13207–13215.
47.
HoogerbruggeP.M., Van BeusechemV.W., FischerA., et al. (1996). Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther., 3, 179–183.
48.
HsiaoW.C., SungS.Y., LiaoC.H., et al. (2012). Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth. Mol. Pharm., 9, 1396–1408.
49.
HuJ.C., CoffinR.S., DavisC.J., et al. (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res., 12, 6737–6747.
50.
IdemaS., CarettiV., LamfersM.L., et al. (2011). Anatomical differences determine distribution of adenovirus after convection-enhanced delivery to the rat brain. PLoS One, 6, e24396.
51.
ItoH., AokiH., KuhnelF., et al. (2006). Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J. Natl. Cancer Inst., 98, 625–636.
52.
JiangH., WhiteE.J., Rios-VicilC.I., et al. (2011). Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J. Virol., 85, 4720–4729.
53.
JingY., TongC., ZhangJ., et al. (2009). Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res., 69, 1459–1468.
54.
KanervaA., NokisalmiP., DiaconuI., et al. (2013). Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin. Cancer Res., 19, 2734–2744.
55.
KaufmanH.L., KimD.W., DeraffeleG., et al. (2010). Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol., 17, 718–730.
56.
KimM.K., BreitbachC.J., MoonA., et al. (2013). Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci. Transl. Med., 5, 185ra63.
57.
KleijnA., KloezemanJ., Treffers-WesterlakenE., et al. (2014). The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity. PLoS One, 9, e97495.
58.
Konopka-AnstadtJ.L., MainouB.A., SutherlandD.M., et al. (2014). The Nogo receptor NgR1 mediates infection by mammalian reovirus. Cell Host Microbe, 15, 681–691.
59.
KroemerG., and LevineB. (2008). Autophagic cell death: the story of a misnomer. Nat. Rev. Mol. Cell Biol., 9, 1004–1010.
60.
KuhlmannK.F., Van GeerM.A., BakkerC.T., et al. (2009). Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma. Cancer Gene Ther., 16, 585–597.
61.
KuhnI., HardenP., BauzonM., et al. (2008). Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One, 3, e2409.
62.
LabbeK., and SalehM. (2008). Cell death in the host response to infection. Cell Death Differ., 15, 1339–1349.
63.
LamfersM.L., GrillJ., DirvenC.M., et al. (2002). Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res., 62, 5736–5742.
64.
LamfersM.L., GianniD., TungC.H., et al. (2005). Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res., 65, 9398–9405.
65.
LamfersM.L., FulciG., GianniD., et al. (2006). Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol. Ther., 14, 779–788.
66.
LamfersM., IdemaS., Van MilligenF., et al. (2009). Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection. Cancer Lett., 274, 78–87.
67.
LiQ.X., LiuG., and ZhangX. (2012). Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine. Curr. Pharm. Biotechnol., 13, 1773–1785.
68.
LiuT.C., HwangT., ParkB.H., et al. (2008). The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol. Ther., 16, 1637–1642.
69.
MagnussonM.K., KraaijR., LeadleyR.M., et al. (2012). A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer. Hum. Gene Ther., 23, 70–82.
70.
McDonaldC.J., ErlichmanC., IngleJ.N., et al. (2006). A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res. Treat., 99, 177–184.
71.
MillerC.G., and FraserN.W. (2000). Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res., 60, 5714–5722.
72.
MillerC.G., and FraserN.W. (2003). Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol. Ther., 7, 741–747.
73.
MorrisonJ., BriggsS.S., GreenN., et al. (2008). Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol. Ther., 16, 244–251.
74.
NakanoK., TodoT., ChijiiwaK., and TanakaM. (2001). Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol. Ther., 3, 431–437.
75.
NakashimaH., KaurB., and ChioccaE.A. (2010). Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev., 21, 119–126.
76.
ObeidM., PanaretakisT., TesniereA., et al. (2007). Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from “silent” to immunogenic. Cancer Res., 67, 7941–7944.
77.
OosterhoffD., PinedoH.M., WitloxM.A., et al. (2005). Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24. Gene Ther., 12, 1011–1018.
78.
OsantoS., BrouwenstynN., VaessenN., et al. (1993). Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. Hum. Gene Ther., 4, 323–330.
79.
PardollD.M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer, 12, 252–264.
80.
ParkB.H., HwangT., LiuT.C., et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol., 9, 533–542.
81.
PrestwichR.J., ErringtonF., IlettE.J., et al. (2008). Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin. Cancer Res., 14, 7358–7366.
82.
RotsM.G., ElferinkM.G., GommansW.M., et al. (2006). An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents. J. Gene Med., 8, 35–41.
83.
SchagenF.H., WensveenF.M., CaretteJ.E., et al. (2006). Genetic targeting of adenovirus vectors using a reovirus sigma1-based attachment protein. Mol. Ther., 13, 997–1005.
84.
SchagenF.H., GraatH.C., CaretteJ.E., et al. (2008). Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice. Hum. Gene Ther., 19, 783–794.
85.
Schenk-BraatE.A., KapteinL.C., HallemeeschM.M., et al. (2007). Gene therapy in The Netherlands: highlights from the Low Countries. J. Gene Med., 9, 895–903.
86.
SchenkE., EssandM., KraaijR., et al. (2014). Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer. Hum. Gene Ther. Clin. Dev., 25, 7–15.
87.
SchrierP.I., BernardsR., VaessenR.T., et al. (1983). Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature, 305, 771–775.
88.
SebestyenZ., de VrijJ., MagnussonM., et al. (2007). An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. Cancer Res., 67, 11309–11316.
89.
SenzerN.N., KaufmanH.L., AmatrudaT., et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol., 27, 5763–5771.
90.
SiebenM., SchaferP., DinsartC., et al. (2013). Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1. Int. J. Cancer, 132, 2548–2556.
91.
SmakmanN., Van den WollenbergD.J., Borel RinkesI.H., et al. (2005). Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J. Virol., 79, 14981–14985.
92.
SmakmanN., Van der BiltJ.D., Van den WollenbergD.J., et al. (2006). Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther., 13, 815–818.
93.
StanzialeS.F., PetrowskyH., AdusumilliP.S., et al. (2004). Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin. Cancer Res., 10, 3225–3232.
94.
SteeleL., ErringtonF., PrestwichR., et al. (2011). Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumour immune priming. Mol. Cancer, 10, 20.
95.
SzeberenyiJ., FabianZ., TorocsikB., et al. (2003). Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells. Am. J. Ther., 10, 282–288.
96.
TangD., KangR., CoyneC.B., et al. (2012). PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev., 249, 158–175.
97.
TesniereA., ApetohL., GhiringhelliF., et al. (2008). Immunogenic cancer cell death: a key-lock paradigm. Curr. Opin. Immunol., 20, 504–511.
98.
ThirukkumaranC.M., NodwellM.J., HirasawaK., et al. (2010). Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res., 70, 2435–2444.
99.
ThirukkumaranC.M., ShiZ.Q., LuiderJ., et al. (2013). Reovirus modulates autophagy during oncolysis of multiple myeloma. Autophagy, 9, 413–414.
100.
TodoT., RabkinS.D., SundaresanP., et al. (1999). Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther., 10, 2741–2755.
101.
UilT.G., VellingaJ., de VrijJ., et al. (2011). Directed adenovirus evolution using engineered mutator viral polymerases. Nucleic Acids Res., 39, e30.
102.
VacchelliE., EggermontA., Sautes-FridmanC., et al. (2013). Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology, 2, e24612.
103.
ValerioD., DuyvesteynM.G., DekkerB.M., et al. (1985). Adenosine deaminase: characterization and expression of a gene with a remarkable promoter. EMBO J., 4, 437–443.
104.
Van BeusechemV.W., KuklerA., HeidtP.J., and ValerioD. (1992). Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells. Proc. Natl. Acad. Sci. USA, 89, 7640–7644.
105.
Van BeusechemV.W., Van RijswijkA.L., Van EsH.H., et al. (2000). Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Ther., 7, 1940–1946.
106.
Van BeusechemV.W., GrillJ., MastenbroekD.C., et al. (2002a). Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J. Virol., 76, 2753–2762.
107.
Van BeusechemV.W., Van den DoelP.B., GrillJ., et al. (2002b). Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res., 62, 6165–6171.
108.
Van BeusechemV.W., MastenbroekD.C., Van den DoelP.B., et al. (2003). Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther., 10, 1982–1991.
109.
Van den HengelS.K., BalversR.K., DautzenbergI.J., et al. (2013). Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures. Cancer Gene Ther., 20, 507–513.
110.
Van den WollenbergD.J., Van den HengelS.K., DautzenbergI.J., et al. (2008). A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting. Gene Ther., 15, 1567–1578.
111.
Van den WollenbergD.J., DautzenbergI.J., Van den HengelS.K., et al. (2012). Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A. PLoS One, 7, e48064.
112.
VellingaJ., RabelinkM.J., CramerS.J., et al. (2004). Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. J. Virol., 78, 3470–3479.
113.
VerheijeM.H., LamfersM.L., WurdingerT., et al. (2009). Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma. J. Virol., 83, 7507–7516.
114.
VogelsR., ZuijdgeestD., Van RijnsoeverR., et al. (2003). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol., 77, 8263–8271.
115.
WesselingJ.G., YamamotoM., AdachiY., et al. (2001). Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther., 8, 990–996.
116.
WhiteC.L., TwiggerK.R., VidalL., et al. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther., 15, 911–920.
117.
WitloxA.M., Van BeusechemV.W., MolenaarB., et al. (2004). Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. Clin. Cancer Res., 10, 61–67.
118.
WolchokJ.D., KlugerH., CallahanM.K., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med., 369, 122–133.
119.
WorkenheS.T., and MossmanK.L. (2014). Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol. Ther., 22, 251–256.
120.
WurdingerT., VerheijeM.H., RaabenM., et al. (2005). Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody. Gene Ther., 12, 1394–1404.
121.
YongR.L., ShinojimaN., FueyoJ., et al. (2009). Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res., 69, 8932–8940.
